575 related articles for article (PubMed ID: 15077222)
1. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model.
Ploemacher RE; Johnson KW; Rombouts EJ; Etienne K; Westerhof GR; Baumgart J; White-Scharf ME; Down JD
Biol Blood Marrow Transplant; 2004 Apr; 10(4):236-45. PubMed ID: 15077222
[TBL] [Abstract][Full Text] [Related]
2. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
3. Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2003 Jul; 32(1):15-22. PubMed ID: 12815473
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients.
Westerhof GR; Ploemacher RE; Boudewijn A; Blokland I; Dillingh JH; McGown AT; Hadfield JA; Dawson MJ; Down JD
Cancer Res; 2000 Oct; 60(19):5470-8. PubMed ID: 11034090
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
8. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
9. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
13. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
14. Toward a myeloablative regimen with clinical potential: II. Treosulfan induces specific skin graft tolerance across haploidentical MHC barriers.
van Pel M; van Breugel DW; Vos W; Ploemacher RE; Boog CJ
Bone Marrow Transplant; 2004 Jan; 33(2):153-9. PubMed ID: 14661037
[TBL] [Abstract][Full Text] [Related]
15. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation.
Xu H; Chilton PM; Huang Y; Schanie CL; Yan J; Ildstad ST
Transplantation; 2007 Apr; 83(7):954-63. PubMed ID: 17460568
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
[TBL] [Abstract][Full Text] [Related]
17. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy.
Forman D; Tian C; Iacomini J
Mol Ther; 2005 Aug; 12(2):353-9. PubMed ID: 15939670
[TBL] [Abstract][Full Text] [Related]
18. Transient and permanent engraftment potential of murine hematopoietic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs.
Down JD; Ploemacher RE
Exp Hematol; 1993 Jul; 21(7):913-21. PubMed ID: 8100536
[TBL] [Abstract][Full Text] [Related]
19. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
Li S; Salgar SK; Kurimoto Y; Yousem S; Pham SM
J Surg Res; 2008 May; 146(2):289-97. PubMed ID: 18314139
[TBL] [Abstract][Full Text] [Related]
20. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
